A US register cannot quote Motilium because no NDA landed

Why a US counter has no Motilium price

Name the hold: no US NDA, no licensed shelf, no cash table.

Because there is no Motilium on the shelf. Domperidone is used in many countries for nausea and slow emptying. The United States never approved a commercial NDA for that tablet. A pharmacist who looks it up in the usual dispensing software will not return a cash price the way they would for metoclopramide.

People still type 'Motilium price' and expect a GoodRx row. The first-pass is to say the row does not exist. No US counter price is not a bargaining stance. It is the regulatory fact.

QT risk is why regulators elsewhere tightened dose and duration, and why the US file never cleared. That is a clinical hold if someone later obtains the drug through an expanded-access or compounding path. It is not a reason to invent a retail band.

Online Motilium ads are not a US NDA

An ad is not an approval. Close the tab that pretends otherwise.

Search will surface overseas carts and Motilium storefront ads. Those ads are not a substitute for an FDA-approved product. A blister pack shipped from another country does not become a US fill because the pixel looks like a pharmacy.Lactation forums still pass Motilium around as a milk-supply trick. That use was never a US labeled indication. A first-pass note does not help someone place an order. It tells them the product they saw in a screenshot is not sitting behind a US counter.

If nausea or gastroparesis is the real problem, the next sentence is an approved US option and a clinician - not a tracking number.

What a first-pass note does when there is no shelf

Three sections, zero dollars. That is the triage, not a missing spreadsheet.

It refuses the table. Other HIM notes list licensed US cash bands when a generic actually sits at Walmart or Costco. Domperidone does not. Padding four chains here would teach the wrong lesson: that every brand name has a coupon.

The useful first-pass is short. Confirm the indication. Ask what US-labeled drug the clinician would write instead. If someone already swallowed tablets from an overseas bottle, that is a toxicity and rhythm conversation, not a price conversation.

HIM is not a pharmacy and will not 'source' Motilium. No US counter price means exactly that.

A familiar drug abroad, a regulatory blank in the US

Domperidone is used worldwide for nausea and slow stomach emptying, and is simply not FDA-approved in the United States. Both facts belong in the first sentence.

Domperidone is a household name for stomach trouble across much of Europe, Asia, and beyond, sold as Motilium for nausea and the bloated, too-full feeling of slow stomach emptying. American readers often meet it first in online forums, especially around breastfeeding, and are surprised to learn it is not approved by the FDA at all.

That regulatory gap is not because the drug does nothing. It is because its heart-rhythm risk, weighed against fairly modest benefits, did not clear the US bar. So the same molecule is a pharmacy staple in one country and an unapproved import in another.

The most useful thing to give a patient up front is that context: where you are changes how you get it, but the underlying pharmacology and the rhythm caution travel with the drug wherever it is used.

It is also worth naming what domperidone is not. It is not a cure for reflux, not a fix for the nerve damage behind diabetic gastroparesis, and not a first-choice antiemetic when better-studied options exist. It is a targeted tool for a specific problem - a stomach that will not empty and the nausea that comes with it.

Patients coming from the breastfeeding forums are the group most likely to be surprised by the cardiac caveat, because the online conversation is almost entirely about milk supply and rarely about heart rhythm. Meeting them with the full picture, benefit and risk together, respects both their goal and their safety.

It helps to separate the two jobs the drug does. As a prokinetic it pushes a sluggish stomach to empty; as an antiemetic it blunts nausea signals. Most patients are prescribed it for one job, but understanding that it does both explains why the same low dose before meals serves such different-seeming complaints.

None of this makes it a first reach for ordinary indigestion. Simple reflux and everyday nausea have gentler, better-studied options, and reserving domperidone for genuine motility problems keeps its cardiac risk in proportion to what it is actually buying the patient.

Blocking dopamine, but staying out of the brain

The selling point is a dopamine blocker that largely stays out of the brain, avoiding the movement side effects that plague metoclopramide.

Dopamine, acting on D2 receptors, tends to relax the stomach and can trigger the brain's vomiting center. Domperidone blocks those receptors, which speeds up stomach emptying and dampens nausea.

Its clever feature is that it barely crosses the blood-brain barrier. Metoclopramide, its older relative, gets into the brain freely and causes restlessness, movement disorders, and occasionally permanent tics. Domperidone mostly stays peripheral, so it spares patients most of that neurological baggage.

It does still reach one spot the barrier does not protect - the trigger zone that senses blood-borne nausea signals - which is part of why it works as an antiemetic. It also raises the milk hormone prolactin, which is the basis for its off-label use to boost breast-milk supply.

The heart connection sits in the mechanism too. Beyond dopamine, domperidone can block a potassium channel that heart muscle uses to reset between beats. Slow that reset and the electrical recovery of the heart stretches out - the QT prolongation that is the drug's defining hazard. So the same molecule that helpfully ignores the brain unhelpfully pays attention to cardiac ion channels.

The prolactin rise is worth dwelling on because it drives both a side effect and an off-label use. By blocking dopamine's brake on the pituitary, domperidone lets prolactin climb, which can cause breast tenderness and milk secretion in anyone and is the entire basis for using it to build breast-milk supply.

That the drug barely enters the brain is not a small design detail; it is the whole reason to choose it over metoclopramide. The movement disorders that make long-term metoclopramide risky come from dopamine blockade inside the brain, and domperidone mostly sidesteps that by staying in the periphery.

The exception, the vomiting trigger zone that sits outside the protected barrier, is a feature rather than a flaw. Reaching that zone is how domperidone quiets blood-borne nausea signals, which is why it works for the queasiness of migraine or of dopamine-boosting Parkinson's drugs without worsening movement.

Short-acting, and cleared by the usual enzyme

Domperidone is taken before meals because that is when you want the stomach primed to empty. Its effect is relatively short, so it is dosed several times a day rather than once.

It is broken down by the liver's CYP3A4 enzyme, which sets up its most dangerous interactions: drugs that block that enzyme raise domperidone levels, and higher levels are exactly what drives the heart-rhythm risk.

Because of that, the modern guidance everywhere it is approved is to use the lowest effective dose for the shortest time, rather than open-ended daily therapy.

Its oral availability is fairly low and variable because the liver processes a good deal of it before it reaches the circulation. That first-pass handling is usually a safety margin, but it also means anything that jams CYP3A4 can push levels up sharply rather than gently - which is why the interaction list matters more than the raw dose alone.

The short duration is why domperidone is a before-meals, several-times-a-day drug rather than a once-daily one. You want it present when food arrives and the stomach needs prompting, not lingering at a steady background level through the night.

Because the liver clears it through CYP3A4, the interaction that matters most is not another QT drug but anything that jams that enzyme. Block the clearance and levels climb, and with domperidone climbing levels mean climbing cardiac risk, so the enzyme interactions and the rhythm risk are really one problem seen from two angles.

The low, variable availability also means responses differ between people more than a tidy dose table suggests. That variability is another argument for starting low and judging by effect rather than assuming a standard dose behaves identically in everyone.

Why a faster stomach helps

The symptoms domperidone targets come from food sitting in the stomach too long: early fullness, bloating, upper-belly discomfort, and the nausea that a stretched, stagnant stomach generates. Coordinating and strengthening the emptying contractions relieves that whole cluster at once.

In gastroparesis, the stomach's own pacemaker and nerves are impaired, often from diabetes or after surgery. Domperidone does not repair that damage; it works around it by recruiting the dopamine brake and releasing it, which lets the remaining machinery push harder.

This is why the benefit tends to track with how much of the problem is genuinely slow emptying versus other causes of the same symptoms. A patient whose nausea comes from a different source will get less from a prokinetic, no matter how logical it looks on paper.

It also explains the before-meals timing. You want the drug on board when food arrives, so the stomach is primed to move it along rather than letting it pool and ferment.

The contractions domperidone helps coordinate start high in the stomach and sweep downward, and it also tightens the valve between the stomach and the food pipe, which is part of why it can ease the reflux-like fullness some patients describe. It is not an acid drug, but a stomach that empties promptly refluxes less.

This is also why domperidone does little for symptoms that are not actually about slow emptying. Functional dyspepsia, anxiety-driven nausea, and pain from other sources all mimic the picture of a sluggish stomach, and a prokinetic aimed at motility will underwhelm when motility was never the real problem.

The practical test, then, is diagnostic as much as therapeutic. A clear response to domperidone suggests slow emptying was genuinely driving the symptoms; a poor response is a signal to look elsewhere rather than to keep climbing the dose.

Modest, real, and mostly for motility and nausea

Domperidone helps with the symptoms of slow stomach emptying - fullness, bloating, nausea - and works as a general antiemetic. The benefit is real but modest, which is part of why regulators weighed it carefully against the rhythm risk.

In gastroparesis, it is one of a small toolkit of prokinetics, valued precisely because it avoids the neurological side effects that make long-term metoclopramide use risky. For many patients it is the drug that lets them eat more normally without the movement-disorder fear.

The trials behind it are generally small and older, which is part of why regulators weighed the benefit as modest. That thin evidence base is not a reason to dismiss the drug, but it is a reason to be honest that its advantages are incremental rather than dramatic.

Real-world use tells a similar story. Patients often report that domperidone takes the edge off the fullness and nausea and makes meals tolerable, which is a genuine quality-of-life gain even when it falls short of the symptom-free result they hoped for.

The lactation use - increasing milk supply through raised prolactin - is off-label everywhere and rests on smaller studies. It works for some, but it is a decision to make with a clinician who can weigh the heart risk against the benefit, not a forum recommendation to be actioned alone.

It also has a role controlling the nausea that dopamine-boosting Parkinson's drugs can cause, precisely because it blocks dopamine in the gut and trigger zone without crossing into the brain to worsen the Parkinson's itself. That is a neat example of the peripheral selectivity paying off.

For gastroparesis specifically, the honest framing is symptom management, not repair. The drug can make eating more comfortable and cut the nausea and fullness, but the damaged stomach nerves and pacemaker are untouched, so it is a way to live better with the condition rather than a cure for it.

The migraine role is underappreciated. Nausea and a stalled stomach during an attack can stop oral painkillers from being absorbed, and a prokinetic antiemetic both settles the nausea and helps the stomach move the analgesic along, which is a genuinely clever piece of combination thinking.

Set expectations honestly on all of it. The benefit is real but modest, and a patient who expects domperidone to abolish their symptoms will be disappointed and tempted to push the dose, which is exactly the move that trades a small extra benefit for a real rise in cardiac risk.

Lowest dose, shortest time

Where it is approved, typical adult dosing is a low milligram amount taken before meals, for as short a period as possible. The days of high open-ended doses are over precisely because of the rhythm data.

It is avoided or used with great caution in older patients, in anyone with existing heart or rhythm disease, and in people with electrolyte problems, all of which raise the QT danger.

Because it is unapproved in the US, there is no FDA-sanctioned dose there; patients importing it are outside a regulated framework, which is itself a safety caution worth stating.

A sensible course is time-limited with a clear review point. If symptoms have not improved within a couple of weeks, pushing the dose higher usually adds cardiac risk faster than it adds benefit, so the better move is to reassess the diagnosis rather than escalate.

The modern approach everywhere it is approved can be summed up in one phrase: lowest effective dose, shortest sensible duration. That is not bureaucratic caution but a direct response to the finding that the rhythm danger scales with dose and with how long levels stay elevated.

Before starting, the checklist is short but non-negotiable: any heart or rhythm history, any current QT-prolonging drugs, and any electrolyte problems, particularly low potassium or magnesium. A patient who clears that checklist and takes a low dose briefly is in a very different risk category from one who does not.

For the breastfeeding use, non-drug measures to build supply come first, and if domperidone is used it should be time-limited with a clear plan to stop, not an open-ended habit that quietly runs for months while the cardiac exposure accumulates.

Where an intravenous form was once used, that route has largely been abandoned because it produced the sharpest rhythm dangers; the oral, low-dose approach is what remains, deliberately gentler in how quickly it raises drug levels.

The instruction to take it before meals is not incidental. You want the stomach primed to empty when food arrives, and taking it afterward misses the window when the prokinetic push is most useful, so timing is part of the prescription rather than a suggestion.

For chronic problems like gastroparesis, courses are kept as short and low as symptoms allow, with periodic attempts to reduce or pause, because the cardiac risk tracks cumulative exposure and open-ended high-dose use is precisely what the modern guidance moved away from.

QT drugs and enzyme blockers

The dangerous combinations are with other drugs that prolong the QT interval - certain antibiotics like the macrolides, some antifungals, and various heart and psychiatric drugs - because the effects add up toward a serious rhythm disturbance. The same QT caution applies to the antiemetic use of domperidone alongside the unrelated wakefulness drug modafinil only insofar as any added cardiac stress deserves a second look.

Just as important, strong blockers of the CYP3A4 enzyme (again, macrolide antibiotics, azole antifungals, and some HIV drugs) raise domperidone levels, indirectly increasing the same rhythm risk. This is the double hit: some of these drugs both prolong QT themselves and push domperidone levels up.

Low potassium or magnesium makes the heart more vulnerable, so anything that depletes those - including aggressive use of a loop diuretic like furosemide - compounds the danger. A patient on a water pill who then takes domperidone is exactly the setup regulators worried about.

Steroids can also lower potassium, so someone on a course of prednisolone sits a little closer to the edge of the same rhythm problem. None of these combinations is subtle once you know to look for them.

The single most dangerous scenario is the patient handed a macrolide antibiotic for a chest infection while already on domperidone. The macrolide both prolongs QT itself and blocks the enzyme clearing domperidone, so it stacks two hits at once, and it is common enough to deserve a specific flag.

Antifungals of the azole family and several HIV drugs pull the same enzyme-blocking trick, and various psychiatric and heart drugs add their own QT effect. The practical habit is to treat any new prescription as a prompt to re-check the combination rather than assuming a stable regimen stays safe.

The reason these interactions loom so large is that domperidone's own benefit is modest. When a drug offers a small, comfort-level gain, almost any avoidable cardiac risk tips the balance the wrong way, so the threshold for stopping it around a risky combination is deliberately low.

Mostly gentle, with one serious exception

For most people the day-to-day side effects are minor: dry mouth, mild abdominal cramps, headache. The raised prolactin can cause breast tenderness or milk secretion, and menstrual changes.

The exception that defines this drug is cardiac. At higher doses, in vulnerable patients, or when levels climb through interactions, domperidone can prolong the QT interval and, rarely, trigger a life-threatening rhythm. That single risk is why the dosing was cut and why the US never approved it.

The practical implication is to keep doses low and short, and to screen for the rhythm risk factors before starting. The prolactin effects, while less dangerous, are the ones patients most often notice and complain about, and they reverse when the drug stops.

Because it does not cross into the brain, the movement disorders and restlessness that dog metoclopramide are uncommon - which is genuinely the point of choosing domperidone in the first place.

The prolactin-driven effects - breast tenderness, milk secretion, and menstrual changes - are the ones patients most often notice, and they reverse once the drug stops. They are harmless in the medical sense but can be distressing, so it helps to warn people they can happen.

Everything else about the day-to-day tolerability is genuinely mild, which is part of the trap. A drug that feels this gentle invites casual, prolonged use, and the whole safety message is that the one serious risk stays silent until it is not - so surface gentleness is no reason to relax about dose and duration.

The rhythm is what to fear

In overdose, the concern is not the stomach - it is the heart. Excessive domperidone can prolong the QT interval enough to provoke a dangerous ventricular rhythm, and that, not sedation or gut symptoms, is what makes a large ingestion an emergency.

There is no antidote. Management centers on cardiac monitoring, correcting any low potassium or magnesium, and being ready to treat a serious arrhythmia. Drowsiness and mild movement effects can occur too, but they are secondary to the rhythm question.

The people at real risk from an overdose are those already carrying QT risk factors - older adults, heart disease, electrolyte problems, or a stack of other QT-prolonging drugs. In a young person with a normal heart and normal electrolytes, the margin is wider, but it is not a drug to gamble with.

This toxicity profile is precisely why importing an unregulated supply and self-dosing is unwise: without the dose caps and screening that framework provides, a person can drift into exactly the territory the rhythm warnings describe.

The warning signs of the dangerous rhythm are worth teaching directly: fainting or near-fainting, sudden palpitations, and a racing or irregular heartbeat. Those symptoms on domperidone are not to be watched and waited on - they are a reason to stop and be assessed, because the rhythm disturbance can be abrupt.

Correcting low potassium and magnesium is a central part of both preventing and managing the toxicity, because a depleted patient's heart is primed for the very arrhythmia the drug can trigger. In someone on a water pill or a steroid, checking and replacing those minerals is not an afterthought.

Historically, the sharpest signal came from intravenous and high-dose use, which is why injectable domperidone fell out of favor and oral dosing was capped. The oral, low-dose, short-course version most patients take today sits well inside a safer margin, provided the risk factors have been screened.

Older patients, hearts at risk, and breastfeeding

Older adults and anyone with heart disease or a rhythm history sit at the sharp end of the QT risk and are the people in whom domperidone is most often avoided.

For breastfeeding mothers considering it to boost supply, the honest framing is that it may help but is off-label and carries a heart risk, so it is a shared decision with a clinician, not a forum recommendation. Non-drug measures to build supply come first.

In the US specifically, there is no approved product, and importing an unregulated supply removes the safeguards that dose limits abroad are meant to provide.

In significant liver disease, clearance falls and levels can climb, so it is used cautiously if at all, since higher levels feed straight back into the rhythm risk. Children are dosed carefully by weight where it is used at all, given the same cardiac considerations.

The people who most want domperidone and the people in whom it is riskiest overlap uncomfortably. Older patients with gastroparesis, often diabetic, frequently carry exactly the heart disease and electrolyte fragility that make the QT risk real, so the group with the strongest indication needs the most careful screening.

For anyone importing it into a country where it is unapproved, the loss of the regulatory framework is itself a hazard. The dose caps, the labeling, and the screening advice that make it reasonably safe abroad simply do not travel with a package ordered online.

Domperidone versus the other options

The natural comparison is metoclopramide, which crosses into the brain and can cause restlessness, acute movement reactions, and, with prolonged use, tardive dyskinesia that may not reverse. Domperidone trades that neurological risk for a cardiac one - a swap many clinicians and patients prefer when movement side effects are the bigger fear.

Erythromycin, an antibiotic, also speeds stomach emptying and is sometimes used short term for gastroparesis, but its effect fades quickly and it carries its own QT and interaction issues. It is a stopgap more than a maintenance choice.

As a plain antiemetic, domperidone competes with better-studied and more widely available options, so its main niche is really the motility problem plus nausea, or the specific case of nausea from Parkinson's medication where its peripheral action is an advantage.

The unusual part of its profile is regulatory rather than pharmacological: a drug considered good enough for routine use across much of the world and simply not approved in the United States, which shapes access far more than any head-to-head efficacy difference.

The cleaner way to frame the metoclopramide comparison is as a choice of which organ you are willing to put at risk. Metoclopramide risks the brain and movement; domperidone risks the heart's rhythm. For a patient terrified of a movement disorder, or already on other neurological drugs, that trade often favors domperidone.

Erythromycin as a prokinetic is a useful short-term tool, especially in hospital, but its effect fades quickly as the body adapts, and it carries its own QT and interaction baggage. It is a sprint drug, not a marathon one, which is why domperidone still occupies the chronic-management niche where it is available.

Clearing up the confusion

The most persistent myth is that being unapproved in the US means the drug is dangerous or fake. It is neither - it is a genuine, widely used medicine whose specific cardiac risk did not clear one regulator's bar. Available elsewhere is not the same as unsafe, and vice versa.

A second misconception is that it treats reflux. It can help the nausea and fullness that accompany slow emptying, but it is not an acid drug and is not a substitute for the treatments that actually reduce reflux.

In breastfeeding circles it is sometimes framed as a harmless supply booster. The prolactin effect is real, but so is the heart risk, and the online enthusiasm often skips the cardiac screening that responsible use requires.

Finally, more is not better. Because the danger scales with dose and level, the instinct to push the dose when symptoms persist is exactly backwards - it raises risk faster than benefit, and the right response is usually to rethink the diagnosis.

There is also a belief that because it is old and widely used, it must be thoroughly benign. Long familiarity is not the same as harmlessness; the rhythm signal only became clear once the drug had been used at scale for years, which is a reminder that time on the market and safety are not identical.

And some assume the breastfeeding use is well established because it is so widely discussed. The prolactin effect is real, but the evidence rests on smaller studies, the use is off-label everywhere, and the enthusiasm online routinely outruns what the data can actually support.

Why the US shelf is empty

Why can't I get it in the US? Because the FDA judged its heart-rhythm risk too high relative to its modest benefit to approve it. It is available and used in many other countries under dose limits.

Is it safe for my heart? For most people with a normal heart, at a low dose for a short time, the risk is small. It rises with higher doses, older age, existing heart disease, low potassium or magnesium, and certain other medicines.

Can I take it long term for gastroparesis? Sometimes, but the aim is the lowest dose that helps and regular reassessment, not indefinite high-dose use, precisely because the cardiac risk accumulates with exposure.

Will it help my milk supply? It may raise prolactin and help some mothers, but it is off-label, carries a heart risk, and should be a clinician-guided decision after non-drug measures rather than a self-started forum remedy.

How quickly will it work? For nausea and fullness the effect is fairly prompt, within days rather than weeks. If a couple of weeks bring no improvement, that is a signal to reassess rather than to push the dose higher.

Can I take it with my other medicines? Usually, but check specifically for antibiotics, antifungals, and heart or psychiatric drugs, since some of those either raise domperidone levels or stress heart rhythm. A quick medication review before starting is worth the trouble.

Is the breast tenderness or discharge dangerous? It is a harmless effect of raised prolactin and it reverses when you stop the drug, though it can be uncomfortable or alarming. Mention it to your clinician if it bothers you.

What to say when there is no US bottle

Take it before meals, use the lowest dose that works, and do not treat it as an open-ended daily medicine. Tell your clinician about any heart-rhythm history.

Flag any new antibiotics or antifungals, since some of them both raise domperidone levels and stress heart rhythm at the same time. The same goes for water pills and steroids that can drop your potassium.

In the US, remember it is not FDA-approved; discuss with a clinician rather than relying on imported supplies without oversight.

If you notice fainting, palpitations, or a racing, irregular heartbeat, stop and seek help - those are the symptoms that matter most with this drug.

If it has not clearly helped within a couple of weeks, say so rather than quietly taking more. A drug that is not working is not a reason to increase the dose; it is a reason to rethink what is going on.

Do not treat online enthusiasm, especially around milk supply, as medical advice. The benefit is modest and the heart risk is real, so this is a decision to make with a clinician who can screen you first, not one to action from a forum thread.

No US NDA, no invented cash

Domperidone is a peripheral dopamine blocker that eases nausea and slow stomach emptying with far less brain-related trouble than metoclopramide. Its Achilles heel is heart rhythm, which capped its dosing and kept it out of the US market.

Used briefly, at low dose, in the right patient, it is a reasonable prokinetic. Screen the heart, watch the interactions, keep courses short, and reassess rather than escalate when it underperforms.